Lebanon planners approve Eli Lilly manufacturing site in Boone County
The Lebanon Plan Commission voted unanimously Monday to approve Eli Lilly and Co.’s development plan for its two manufacturing facilities in Boone County.
Eli Lilly and Co.
Articles
Following Lilly’s lead, Novo Nordisk plans insulin price cuts
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly and Co.
Lilly’s older Alzheimer’s drug fails to prevent disease in trial
Eli Lilly said the study concludes its clinical development of solanezumab, apparently shutting the door on one of the most closely watched experimental drugs over the past decade.
In ninth try, Eli Lilly asks shareholders to end staggered terms for board members
The Weinberg Center for Corporate Governance at the University of Delaware, a leading voice for responsible corporate leadership, has generally supported the elimination of staggered terms, saying they can lead to entrenched boards and management that fails to perform.
Under growing pressure, Lilly to cut price of popular insulins by 70%
The Indianapolis-based drugmaker also said it will expand a program that caps patient out-of-pocket costs at $35 or less a month.
Downtown’s largest employers bet on hybrid work
Cummins, Rolls-Royce, Eli Lilly and Co., AES and Elevance Health are among the city’s largest downtown employers and all say most of their workers have the option of working at home at least part of the time.
Lilly receives FDA approval for rare blood cancer treatment
Jaypirca was approved to treat mantle cell lymphoma, or MCL. a rare blood cancer that starts in white blood cells in the lymph nodes for which there is no cure, according to Lilly. The disease affects about 1 in 200,000 people worldwide each year.
Lilly to invest another $450M in North Carolina factory
The move will create at least 100 new jobs at the plant, located in Research Triangle Park, the largest research park in the country.
Feds reject Lilly’s fast-track application for Alzheimer’s drug
Donanemab’s ability to rapidly remove amyloid beta from patients’ brains prevented the required number of patients from receiving the drug for a full 12 months, Lilly said, resulting in the FDA rejection.
Lilly plans to construct 12 buildings at LEAP campus in Boone County
The company’s more detailed plans for the project reveal the 12 buildings would range in size from a 3,200-square-foot visitors center to a pair of three-story, 330,000-square-foot manufacturing facilities.
California to sue Lilly, other drug companies over insulin prices
California on Thursday announced it will sue the companies that make and promote most of the nation’s insulin, accusing them of scheming to illegally increase the price of the drug.
Stories about Scott Wise, IMS and Lilly are IBJ’s most-read of 2022
The list—based on the number of times readers clicked on stories—includes several other real estate stories as well, including the future plans for Christel DeHaan’s former estate and a fitness chain’s plans to move into a former Marsh store.
With stock trading near record high, Lilly embarks on ambitious 2023
The Indianapolis-based pharmaceutical company is preparing for one of its most ambitious years in memory for 2023, with plans to advance five new drugs into late-stage clinical studies and move four into regulatory review.
Diabetes drug Lilly abandoned has new life
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.
Eli Lilly’s report card on racial justice effort shows $15.6M in donations
The Indianapolis-based drugmaker released a report card Thursday that outlined its progress “to support effective solutions” to racial inequity and social injustice. In addition to donations, the company has committed tens of millions of dollars to other diversity efforts.
A fake tweet sparked panic at Eli Lilly and may have cost Twitter millions
By Friday morning, Eli Lilly executives had ordered a halt to all Twitter ad campaigns—a potentially serious blow, given that the $330 billion company controls the kind of massive advertising budget that Musk says the company needs to avoid bankruptcy.
Roche’s Alzheimer’s drug fails in fresh blow to fraught field
Gantenerumab’s demise is a boost for Indianapolis-based Eli Lilly and Biogen, which are also developing treatments for Alzheimer’s, said Tim Anderson, an analyst at Wolfe Research. Lilly shares were up 1.8% at midday.
Twitter deals with users impersonating major companies—including Eli Lilly
A Twitter user posing as Indianapolis-based Eli Lilly falsely tweeted that insulin was now free, prompting an apology from the actual company.
Lilly shares stumble on lower profit outlook despite solid quarter
Eli Lilly stock has skyrocketed 36% in the past 52 weeks due to strong sales on newer drugs, but the market reacted negatively to its latest forecast.
Lilly commits $92.5M to Purdue for drug research, scholarships
In a significant expansion of their longstanding collaboration, the partners hope to develop new models for delivering therapies to patients and provide full tuition to between 75 and 100 students each year for 10 years.